[177Lu]Lu-DOTATATE May Resensitize Neuroendocrine Tumors to Hormonal Therapy: Initial Clinical Experience in Renal Carcinoid

A 65-y-old woman was diagnosed with grade I right renal carcinoid after right nephrectomy. For anonymous publication of her case in this article, written informed consent was obtained from the patient. After 2 y of lanreotide treatment, therapy was discontinued because of unresponsiveness. Two